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ABSTRACT
This study will investigate the difference in radiation at different volumes between
traditional electron beam therapy and a novel IMET. The difference in dose absorbed at different
locations of two patients will be recorded. Both patients will be treated with traditional electron
therapy and intensity modulated electron therapy. The dose absorbed will also be recorded with
slight shifts in x, y, and z-directions relative to the incoming beam for cases with and without
intensity modulation. The difference between this new model treatment and the traditional
treatment will be calculated. The difference between shifts of the target area will also be
calculated. The main goal of this project is to determine if the target area is still sufficiently treated
with this slight shift of the patient in different directions, and if IMET is the more efficient
treatment option. The difference in dose observed of the target area and surrounding vital organs
with the shift in the patient is crucial for the success of this project. It will determine if this method
can be implemented in the future for use in radiation therapy treatments, depending on if the target
area is still treated, and the vital organs are not in danger. If successful, this project will mean
IMET can be further evaluated for clinical use for patient care.
KEYWORDS: electron therapy, intensity modulation, radiation, treatment, clinical, medical
physics
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CHAPTER 1: INTRODUCTION
The field of medical physics is constantly evolving and transforming the way the cancer
and other diseases are treated. Technology in the past years has widely impacted what can be
done in cancer research development. One of the most commonly used methods today is
Intensity Modulated Radiation Therapy (IMRT). In South Korea, 70 percent of patients were
treated with IMRT in 2018, which was a drastic increase from the number treated in 2011 [1].
Unlike traditional methods, this treatment utilizes planning algorithms to minimize unwanted
treatment to healthy surrounding tissue.
Radiation therapy, in broad terms, is the destroying of tumors and other targets in the
body with use of radiation. This is easy to do, because if you hold a highly radioactive material
or fire a patient with a high dose of radiation, the cancer would be easily obliterated. The
problem with this is, of course, there would be substantial damage to the person’s surrounding
organs. The goal of radiation therapy is to kill the target volume, stop the advancement and
growth of the illness, and spare the surrounding organs and keep everything that is still operating
healthy and working.
There have been multiple methods cultivated to combat this problem, such as threedimensional conformal radiotherapy (3D-CRT), volumetric modulated arc therapy (VMAT), and
gamma knife radiation therapy [2][3][4]. One of the more practiced methods in treatment is
IMRT. This method, as with the others mentioned, is better formulated for sparing the noncancerous tissue while still eliminating the targeted area.
Besides photons, common different methods include proton therapy and electron therapy.
This project focuses on applying the same method of modulating and formatting incoming beams
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for better treatment with a focus on electron therapy. Before discussing improving electron
therapy, let us look into IMRT and how it is used as a better alternative to traditional photon
therapy.
Intensity Modulated Radiation Therapy (IMRT) is a technique where a patient is treated
with nonuniform photon beams optimized to match a targeted volume. First, a plan is cultivated
for the patient using computer treatment-planning systems with IMRT software. Then, once the
plan is generated, the system that delivers the radiation is appropriately tested to see if it is
suitable for the patient using a “phantom”. A phantom, sometimes referred to as an imaging
phantom, is a material that is used to represent a patient. This device is used before each
individual procedure to guarantee that the system is calibrated and safe to administer radiation to
the patient [5].
Once this is accomplished and given approval to start by the medical physicist, the
patient is brought in for treatment. IMRT requires multiple sessions. A patient is typically
treated five days a week for several weeks, with each meeting lasting from ten to fifteen minutes
[6]. The patient is then delivered a high dosage of modulated photon beams, which have already
been shaped to hit the planned target area while avoiding the surrounding area using dynamic
multileaf collimaters (DMLCs) [7]. These DMLCs are movable fields that are responsible for
adjusting the photon beams.
Purpose and Motivation
This idea of modifying the incoming beam is the ideology behind the ongoing project at
Orlando Health. The goal is to apply this method to traditional electron therapy, resulting in
Intensity Modulated Electron Therapy (IMET). IMET similarly modulates incoming electron
beams to accurately target the cancer while sparing surrounding regions. The difference is that
2

electrons behave much differently than photons, and protons for that matter, when implemented
for treatment of cancer. Overall, this project will apply intensity modulation to electron therapy
and verify if the cancer is treated in a more efficient way, and that the surrounding organs are not
at risk of damage. If successful, this method could be used in practice to treat patients in the
future.
As mentioned previously, radiation treatments for cancer mainly derive from three
sources: photons, protons, and electrons. Each of these classifications, as expected, behave
differently when entering the human body. This causes there to be scenarios where one may
prove more useful than the next. The idea of IMET derived from photon treatments, which will
be discussed in further detail in the Literature Review. IMRT, which implement photons, has
proven to be more effective and beneficial than traditional photon therapy [8]. The notion for the
project at Orlando Health is to apply this shaping of treatment beams to traditional electron beam
therapy, creating a new method of Intensity Modulated Electron Therapy (IMET). This new
method will benefit the patient by saving more healthy cells when applying electron radiation
therapy, as well as limit the number of hotspots and coldspots in treatment by applying a more
homogeneous dose.
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CHAPTER 2: LITERATURE REVIEW
Conventional Radiation Therapy
Two-dimensional photon therapy, often referred to as conventional radiation therapy,
delivers dose to a tumor using massless photons while avoiding the surrounding area. This
traditional external radiation is the most common type of radiation therapy. When radiation
enters the body, it makes small breaks in the DNA inside of cells. These cause the cancer cells
to stop growing, resulting in the death of the cells. It is a localized treatment, unlike
chemotherapy, and only the targeted area and surrounding cells are affected.
Photons are emitted from machines called linear accelerators by a complex system known
as an x-ray tube [9]. Inside of a lead container, a high voltage is applied to cathode filament and
an anode target. The filament is chosen on the grounds that it must have a high melting point
and atomic number in order to produce electrons. Based on this criteria, pure tungsten is
commonly used. When the filament is charged, electrons accumulate on its surface causing the
material to heat up. The electrons are then released during a process called thermionic emission
[10].
The electrons accelerate towards the anode target inside of a vacuum chamber. The
anode, in turn, converts the energy of the accelerated electrons into x-ray photons and heat [9].
This anode is rotated to accommodate for the build-up of heat and the photons are directed out of
the chamber by an aluminum filter and are used to treat the patient. The efficiency of the
photons emitted is proportional to the atomic number Z of the target and voltage of the tube. The
intensity of the x-ray photons with no filtration can be solved mathematically by Kramer’s law
[11]:

4

𝑑𝑰(𝝀) = 𝐾

𝝀
𝝀

− 1

1
𝑑𝝀
𝝀

Equation 1- Kramer’s Law.

In Equation 1, I is the intensity of the photon, K is a constant proportional to the atomic number,
𝝀 is the wavelength of the radiation, and 𝝀

is the shortest allowed wavelength from the linear

accelerator.
Conventional Radiation Therapy at Orlando Health
Currently Orlando Health, as well as almost any hospital that offers treatment in
radiation, administers conventional radiation therapy. This method of treatment is the most
studied and widely used procedure for cancer treatment and is being further developed to treat
people more efficiently.
Intensity Modulated Radiation Therapy (IMRT)
IMRT is a more modern high precision photon therapy. In this approach, there are two
additional systems required than in the previous method [7]. A linear accelerator is still needed
to extract and emit photons using the x-ray tube previously explained. To enhance and improve
the treatment, a computer with IMRT software is needed to plan the modulation of the beam. A
beam delivery system including DMLCs must also be present in order to accommodate the
photons to match the plans generated from the software.
As seen in the previous section, the intensity of the beam is proportional to the voltage
applied to the tube in the linear accelerator. By applying several voltages, various beams can be
formatted to precisely destroy the targeted cancer. If nonuniform beams from the computergenerated algorithms are included, then the radiation beams can much more accurately fit the
shape of the tumor, thus limiting the damage to the surrounding area. This algorithm-based
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technique is being practiced more frequently in recent years, as shown in Figure 2.1 below
obtained from Radiation Oncology Journal [12].

Figure 2.1- Various cancer patients treated with IMRT in metropolitan areas from 2011 to 2018 [12].

IMRT has been shown to have lesser side effects for lung cancer patients [13]. For
prostate cancer, the survival rate using this method has been shown to be 98.8 percent [14]. It
also has been shown to reduce moderate to severe xerostomia and subcutaneous fibrosis when
compared to other radiation methods [15]. Photons are advantageous in some ways for treatment
because they are generally easier to extract and modify to treat a specific area. However, in
some cases it proves to more beneficial to use protons, and in other cases electrons. The best
plan for treatment of diseases depends on numerous factors, including the type of tumor, the
location in the body, if there are vital organs that cannot absorb much radiation at all (for
instance, the spinal cord), etc. Photons, when released, will continue throughout the body, which
is not the case for electrons, making this method useful for targets at further depth inside the
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body. IMRT is generally new compared to other treatment methods, and as with anything can
still be improved.
IMRT at Orlando Health
IMRT is constantly being studied and modified at universities and hospitals throughout
the world, and Orlando Health is no exception. This procedure is much more efficient and
growing in frequency compared to traditional photon treatments. It is a prime example of how
traditional treatments can be further developed into something much more efficient and overall
better for treating people.
Conventional Electron Beam Therapy
Electrons have mass, albeit small, and carry a negative charge. Due to these
characteristics, they are preferable in treating certain types of cancer. Since the 1970’s, high
energy linear accelerators have been able to produce photons and electrons [16]. Electrons are
applied with the same method as photons. The main advantage of using electron beam therapy
as opposed to IMRT and proton therapy is electrons have a sharp drop off in energy. Electrons
release most of their energy relatively close to the skin. Because of this phenomenon, this
treatment is typically used for tumors less than five centimeters deep [16]. Although, it still can
be used to treat cancers at larger depths by increasing the energy at which the electrons are
released from the linear accelerator. This therapy can be favorable for treating skin cancers,
lymph nodes, breast cancers, and head and neck cancers.
Electron beam therapy typically prioritizes energy levels from 6 to 20 MeV. In water,
which has similar properties to soft tissue, the rate of energy loss is approximately 2 MeV/cm
[16]. Electrons have a mass of 9.11 x 10-31 kg, as opposed to massless photons. This means
greater energy distribution, making this choice of treatment ideal for tumors closer to the skin.
7

With each treatment, there are areas that absorb less and more radiation, called coldspots and
hotspots respectively. These can pose as a problem as some areas will not get the sufficient
amount of treatment while others receive too much, which can not only be painful for the patient
but also have other risks to health of the cells surrounding. With optimization to the electron
beams, this issue can be resolved, which leads us to the focus of this project.
Electron Beam Therapy at Orlando Health
Electron beam therapy is a field that is used for distinct types of scenarios compared to
photon and electron therapy. This treatment type is the basis of what the ongoing research at
Orlando Health, and this thesis, is focused on. Electron beam therapy can be further modified to
treat cancer in a more effective and optimal way by providing a more conformal and uniform
dose.

8

CHAPTER 3: METHODOLOGY
Formulating the Research Question
As stated before, radiation therapy is the killing and destroying of tumors with radiation.
The goal of this type of therapy is to limit the surrounding healthy tissue, while maximizing the
dose to the target to still expose of the disease. Of the different types of radiation therapy, each
have their pros and cons. In the Literature Review, it was found that electrons stop in the body.
This is due to the fact that they are negatively charged, and they do not travel linearly once they
enter the patient due to different densities of structures in the way. This makes them the ideal
type of treatment for tumors located near the skin, especially in the head/neck region. Below is
an example of conventional electron therapy.

Figure 3.1- Close up of conventional electron therapy of a patient.
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In Figure 3.1, a patient’s head being treated with conventional electron therapy with
distinguished, critical organs outlined. In this case, the teal-colored shape at the tip of the nose is
the target volume (the tumor), the left eye is the green-colored circle, and the right eye is the
red/orange-colored circle. Figure 3.1 gives a nice visual of how different amounts of radiation
are absorbed throughout the body. The red-shaded areas represent hotspots, or areas that receive
a plethora of radiation. The dark blue-shaded areas likewise represent the coldspots, or areas that
receive minimal radiation.
As Figure 3.1 above shows, the electrons when applied with no modifications or barriers
to help the patient have dramatic effects. The problem with conventional electron therapy is that
electrons are all fired from the linear accelerator at the same speed. In turn, the electrons all
relatively travel to the same depth in the body. This will certainly treat the target area, but the
electrons all go further to the same depth. This is not ideal when trying to limit the damage
caused by radiation to healthy surrounding cells. Therefore, this treatment plan can be improved
by modifying the conformity of the beam.
To combat this issue, dotDecimal, a company that works with Orlando Health and other
hospitals throughout the country, have developed a plastic “barrier” called a bolus. A bolus is an
object that is individualized for each patient. This means a patient is brought in, and depending
on the shape of the tumor, the densities of the surrounding organs, any air pockets within the
body, and the overall uniqueness of the person, a bolus will be calculated to accommodate for all
these things. The bolus will then be placed on top of the patient with optimized thickness to
control how far electrons will travel into the body depending on where the cancer is and what is
surrounding it. Below in Figure 3.2 is the same plan as above, but now including a bolus.
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Figure 3.2- Close up of conventional electron therapy with application of a bolus.

The bolus, outlined in dark blue, is placed above the patient between the incoming electrons. In
this plan, it is seen that the bolus is shaped to be thick on the sides to prevent electrons from
traveling further on the sides, and shaped accordingly in the middle to prevent electrons from
travelling further into the body.
When comparing the last two figures, it is shown that with the bolus, the range of how far
the electrons travel within the body are controlled. In the case without the bolus, the electrons
travel much farther and to the sides of the head, almost to the point of reaching the brain. With
the bolus, electrons do not travel nearly as far, improving the patient plan altogether by sparing
healthy tissue. Still, the plan can be developed further. In Figures 3.3 and 3.4 below, there are
two examples of the bolus (in blue) along with copper cutouts (in red). These copper squares are
used to shape the beam to match the target volume’s shape.
11

Figure 3.3- Visual of bolus placed on patient. This patient is the same as the one shown in Figures 3.1, 3.2.

Figure 3.4- Another visual of bolus, this time on another patient.

As it is now, there is a much more conformal dose, meaning that the beam is formatted to
control the depth of the treatment. Looking at Figure 3.2, however, it is shown that there are still
multiple hotspots and coldspots within the patient. So, in order to achieve a better overall
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outcome in treatment, there must be not only a conformal, but a more uniform and homogeneous
dose as compared to conventional electron therapy.
To resolve this issue, Orlando Health and dotDecimal introduced intensity modulated
electron therapy (IMET). IMET is the focus of this project, and is still only in the research phase
of being implemented to treat patients. As explained in the Introduction, IMET is similar to
IMRT in that it should provide a more effective and improved way of treatment as opposed to its
conventional treatment foundation. With IMET, the beam will be more homogeneous, and
should limit the intensity of the hotspots and coldspots.
IMET will be individualized for each patient. Much like how the bolus will me made
according to the structures and shapes of the patient, so will intensity modulation. The concept
of this plan is tungsten pins will be placed inside the copper cutouts attached to the end of the
beam source seen above in Figures 3.3 and 3.4. Each pin will be placed in a specific location,
with the pin’s size depending on how many electrons need to go through. So, to summarize, the
bolus will act as a way of controlling how far the electrons will reach into the patient, and the
intensity modulation pins will control how many electrons travel in each location.
Tungsten will be used to because it is a very dense element. This element is also shown
to be ideal for radiation shielding [17]. A 6 mm pin of tungsten can block 20 MeV of incoming
electrons. Larger pins will absorb more electrons in areas that do not need as much dose. Of
course, in areas that need more dose, there will be lighter pins, or in some areas no pins at all.
This in turn produces a uniform dose, which will benefit the patient and improve the plan.
Below is the same plan shown above in Figures 3.1 and 3.2, but now with intensity modulation
implemented.
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Figure 3.5- Close up of intensity modulated electron therapy (IMET) with a bolus.

In the case above with intensity modulation, the intensity of the hotspots and coldspots
are decreased, meaning that there is a more uniform dose. Below are the same instances as
Figures 3.3 and 3.4, but now including intensity modulation tungsten pins inside the copper
cutouts. These will provide the plan a uniform dose needed to improve overall patient care.
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Figure 3.6- Visual of intensity modulation pins. This patient is the same as the one shown in Figures 3.1, 3.2, and 3.4.

Figure 3.7- Another intensity modulation pins. This patient is the same as in Figure 3.5.

Here multiple tungsten pins responsible for blocking the incoming electrons are shown inside the
copper cutouts. In both cases, there are pins of varying size. As mentioned before, the copper
cut outs will be placed on the end of the beam source, which is the linear accelerator, and not the
actual patient, like the bolus. Below are some examples of real-world images of the tungsten
pins which better show the differing sizes and placements.
15

Figure 3.8- Real example of tungsten pins for intensity modulated electron therapy, provided by dotDecimal.

Figure 3.9- Real example of tungsten pins for intensity modulated electron therapy, provided by dotDecimal.
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Now, there is a conformal and uniform dose. The problems that arise with intensity modulation
lead to the research question.
Research Question
With the application of a bolus and intensity modulation to conventional electron beam
therapy, there is now a conformal and uniform dose. There is now a problem that arises due to
the fact that intensity modulation is formatted in a specific way to accommodate for the unique
density placement of structures, the shape of the tumor, and other instances including air pockets
that need to be considered when planning the pin placement of intensity modulation. The
question is: What if there is a shift in the patient? In the bolus case, this is not a problem simply
because the bolus is attached to the patient. So, when the patient moves, the bolus will as well so
the optimized thickness and conformity is not changed. As previously stated, the copper cutout
and the tungsten pins are placed on the beam source, so a shift in the patient with respect to the
beam source will disrupt the plan specifically designed for vital organ placement and object
densities of each patient.
Typically, a patient being treated with electron therapy comes in five time a week for
anywhere from four to six weeks. During this time, the patient ideally is to be put in the same
exact position each time. This, understandably, is difficult to achieve. Imagine you must go into
a room every day for thirty days straight, and then you must place your hand on a table in the
exact same spot thirty times in a row. Even if you mark the spot on the desk, it is still difficult to
be in the same position down to the millimeter. This is the task clinics must overcome to deliver
radiation therapy. A good clinical setting limits patient movement between two to three
millimeters, but still the question remains: Does this shift affect the healthy organs at risk
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surrounding the cancer, considering that intensity modulation is planned according to the original
position of these organs?
In order to further evaluate IMET and to use this treatment in a clinical setting, there are
key points about IMET that need to be studied. Firstly, and most generally, this project will
determine if IMET will provide an alternative, superior method to conventional electron therapy.
It will also determine if shifting a patient with respect to the incoming electron beam will
damage the organs at risk (OAR) affected by the electron therapy. The location of the pins and
the size of them, as previously mentioned, are formulated based on the original position of the
patient, so does shifting the patient damage the OAR to the point where IMET can’t be
implemented? Does intensity modulation offer a superior method to treating patients? This
project will answer the above points. The intensity modulation of the beam administers a more
homogeneous dose, so this brings us to my hypothesis for the project.
Hypothesis
Intensity Modulated Electron Therapy (IMET) will provide a superior method to treating
cancer as opposed to traditional electron therapy. Shifting the patient with respect to the beam
will not have a drastic negative effect on the patients, and will not put any organs at risk in
danger of irreparable damage. This study should provide an accurate measurement indicating
that the shift in the patient should not have a drastic effect on the overall homogeneous electron
beam treatment.
Experimental Methods
In order to evaluate how IMET compares to traditional electron therapy, and to treatment
with only a bolus, dotDecimal eRT clinical testing software will be utilized to simulate treatment
plans. There will be two different patient plans. Both the prescribed dose of these plans and the
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patients themselves were obtained from Orlando Health. Each patient will have three original
cases with no shifts simulated: one with traditional electron therapy (no bolus or intensity
modulation), one with only bolus, and finally one with a bolus and intensity modulation. Once
they are simulated, the data obtained will be downloaded to a software called ProKnow to
analyze and compare results using a Dose-Volume Histogram (DVH).
A DVH is a graphical representation used by medical physicists to help read the dose
absorbed, in Gray (Gy), by different volumes of organs in the body [18]. One Gray is equal to
one Joule per kilogram [19]. For a patient, a planning target volume (PTV) is a certain volume
(including uncertainties), which will be exposed to radiation [20]. Different organs at risk
(OAR) have extremely low thresholds of how much radiation can be absorbed, like the spinal
cord. An example of a basic DVH is shown below in Figure 3.11 from Physics and Imaging in
Radiation Oncology [21].

19

Figure 3.10- An example of a typical DVH with plans for various target volumes [21].

In the Figure 3.10, each OAR is labeled in the key shown. The volume of the PTV, or in this
case the CTV (clinical target volume), is shown to have more dose (Gy) absorbed as compared to
the OAR. The CTV is simply the PTV including the margin around it.
To gain a better understanding of how to read a DVH, say a PTV is 3 cc, or 3 cm 3. The
PTV is prescribed to be treated with 15 Gy. In a perfect world, 3 cc would be treated with a dose
of 15 Gy, meaning 100 percent of the volume receives 100 percent of the dose. In a DVH, this
would represent a square, and is the best possible treatment of the cancer.
In reality, some small percentage of the volume receives over 15 Gy, which are the
hotspots (located at the bottom right of the graph, past the prescribed dose of 15 Gy). Similarly,
some small percentage of volume is only treated with less than 15 Gy, called the coldspots
(located on the top right, just before the drop off in the line of the DVH). With adjustment to the
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radiation beams, the trendline on a DVH would be closer to the best possible treatment, making
it the better plan. So, by using a DVH of the cases, one can determine if intensity modulation is
the superior method to treating cancer as opposed to conventional electron therapy with only a
bolus by comparing the trendlines of the PTV.
An example of a DVH obtained through simulating in eRT and uploading the data to
ProKnow is shown below. ProKnow software can also be used to determine mean dose absorbed
for each OAR, minimum and maximum dose absorbed, and calculating volume in cc (or cm 3) in
a DVH as opposed to percent total volume.

Figure 3.11- An example of DVH obtained using ProKnow. The x-axis represents the dose absorbed in Gy, and the y-axis is
cumulative volume in %.
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In Figure 3.11, there is an example of a typical DVH with red lines added to help
visualize how to read the graph. In the above example, the solid line represents the original case
with no shifts, the dotted line represents a positive 5 mm shift in the x, y, and z-direction, and the
dashed line represents a negative 5 mm shift in the x, y, and z-direction. The magenta-colored
lines represent the PTV, the yellow represent the right temporal lobe, and the purple lines
represent the parotid gland. If someone wanted to know how much radiation 25 percent of the
total volume of the parotid gland absorbed, by looking at the line it can be seen that with a
positive x, y, and z-shift, about 11 Gy is absorbed, and for a negative x, y, and z-shift about 35
Gy is absorbed. This also works for the vertical line for the PTV. One can determine that for
volumes that absorb approximately 63 Gy include 80 percent of the original case volume, 90
percent volume with negative shift and 91 percent with positive shift.
Once the three original cases are simulated and compared using a DVH, shifts in the
patient with intensity modulation with respect to the beam in different directions will be
conducted. The data for each OAR with the shifts applied will then be analyzed, and finally the
data obtained will be compared to each OAR’s threshold values obtained from Orlando Health.
If none of the values obtained exceed the threshold limits, the OAR are not in danger of being
damaged, confirming the hypothesis.
Once it is determined if IMET is superior to conventional electron therapy and verify that
the OAR are not at risk even with a shift in the patient, treatment plans of only a bolus and
intensity modulation with bolus with the same shift will be compared. This will compare the
effect intensity modulation has on the OAR to the only bolus case. Finally, there will be a
comparison of the shift spreads of the intensity modulated plan with the only bolus plan to
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determine if clinics need to change their practices to treat patients with IMET. The two patients
studied for this project are shown below in Figures 3.12 and 3.13.

Figure 3.12- The Nose Brow patient obtained from Orlando Health. This picture shows the PTV and all OAR.

In Figure 3.12, the same patient shown before in Figure 3.1 and 3.2, the teal outlined
section near the nose is the target volume, the green outline is the left eye, and the red/orange
outline is the right eye. For this patient, the prescribed dose to treat the patient is 60 Gy. It will
be delivered in 30 fractions, each with 2 Gy per fraction. The beam will be delivered with a
Gantry, Couch, and Collimator angle of 0°. This means that the optimal angle to treat this
patient will be head on, with no change in the angle to better reach the tumor (meaning the beam
will come from directly in front of the patient). The energy of the electrons leaving the linear
accelerator will be 9 MeV.
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Figure 3.13- The Brain case patient obtained from Orlando Health. This picture shows the PTV and all OAR.

In Figure 3.13, the same patient shown before in Figure 3.4 and 3.7, the magenta outlined
section on the left side of the picture (the right side of the brain) is the target volume, the small
purple outline in the top right-side view of the patient is the parotid gland, the yellow outline is
the right temporal lobe, and the brown outline is the oral cavity. For this patient, the prescribed
dose is also 60 Gy. It will also be delivered in 30 fractions, with 2 Gy per fraction. However, in
this case the beam will be delivered with a Gantry angle of 304°. The Couch and Collimator
angle are both 0°. This means that the optimal angle to treat this patient will still be in the x-y
plane, with no change in the z-direction. The optimal angle to treat the tumor will be from the
right side of the patient. The energy of the electrons leaving the linear accelerator will be 18
MeV in this case.
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Figure 3.14- Visual of coordinates of patients.

In Figure 3.14, the coordinates of the patients are shown. The patient’s left is the positive
x-direction, toward the patient’s back is the positive y-direction, and from the toes to the
patient’s head is the positive z-direction. In both cases shown in Figures 3.12 and 3.13, the
patient will be analyzed after a shift in the x, y, and z-direction relative to the incoming electron
beam. As mentioned before, a good clinical setting will limit patient movement to about 3 mm.
So, each patient will be shifted 1, 2, 3, and 5 mm in the following directions: ±x-direction (±x,
0, 0), ±y-direction (0, ±y, 0), ±z-direction 0, 0, ±z), and ±x/±z-direction (±x, 0, ±z). The special
case of a shift in the direction of the beam (in this case y-direction) will be evaluated separately
because this shift should not have as much of an impact as the perpendicular x and z-shifts.
Then, each patient will be shifted 3 mm and 5 mm in the ±x, ±y, and ±z-direction (±x, ±y, ±z).
In total, for both patients, there will be a total of 154 different patient plans simulated on eRT,
uploaded to ProKnow, and analyzed to confirm IMET performs better, and all OAR are safe.
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A shift in the direction of the beam will be analyzed separately from the perpendicular
cases because it should not have as much of an effect when compared to the x, z-direction shifts.
The best way to explain this phenomenon is to do so visually, shown in Figure 3.15 below.

Figure 3.15- The special case of a shift in the direction of the beam as compared to perpendicular shifts.

In both patient cases, the Source to Skin Distance (SSD) is over 100 cm (105 cm for Nose Brow,
103 cm for Brain). Therefore, shifting the patient from 1 to 5 mm towards or away from the
beam source will still generally cover the same overall volume. However, the dashed line in the
drawing represents the new area being treated with a perpendicular shift in the x or z-direction.
With a perpendicular shift to the right, there is a much different area being hit with radiation on
the right side. Likewise, a shift to the right in means that the left side of the area that was once
treated now is not getting hit with any radiation, as it is outside of the cone-shaped beam
deliverance. This will be verified if this is the case in the results section.
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If the patient were to shift, this would be viewed as with respect to the beam. So, when
shifting the patient, it is important to adjust the patient accordingly if the beam is at an angle.
For the Nose Brow case, this is straightforward, considering the Gantry/Couch/Collimator were
all 0°. A shift in the patient with respect to the beam in the positive x-direction would be the
same as simply shifting the patient to the left. However, for the Brain case, there must be special
adjustments needed to shift the patient left/right, to/from, or up/down with respect to the beam.

Figure 3.16- Visual of coordinate axis and rotating the beam at a Gantry angle of 304°.

If there is a 304° Gantry angle to the beam, then the beam is being delivered at an angle
of ϴ = 34° from the x-axis. In order to determine the necessary shift with respect to the beam,
there needs to be a change in both the x and y axis. As previously discussed, the beam is still on
the x-y plane, meaning a shift in the z-direction can still be treated the same as the Nose Brow
case. This can be viewed as Φ = 0° in the equation below to solve for height.
𝑧 = ℎ𝑐𝑜𝑠(𝛷)
Equation 2- z-Direction shift.

27

Here, z is the z-direction shift, and h is the height of the shift with respect to the beam. Solving
this equation with Φ = 0° simply gives z = h, meaning that there is no special adjustment needed
for a shift in the z-direction with respect to the beam. Using the ϴ found before, the necessary x
and y adjustments needed to move the patient in the ±x and ±y-directions with respect to the
beam can be calculated.

Figure 3.17- Visual of ±x and ±y-shifts with respect to the beam for the Brain case.

Solving for the ±x-direction shifts with respect to the beam; the necessary x and y
components needed to shift in both directions are solved.

±𝑥 = ±𝑑𝑠𝑖𝑛(ϴ)
±𝑦 = ∓𝑑cos(ϴ)
Equation 3- x-Direction shift with respect to the electron beam.

In Equation 3, the x-direction and y-direction shifts in the coordinate system are denoted x x and
yx to show that they are for x-direction shifts with respect to the beam. Notice that for a positive
x-direction shift with respect to the beam (meaning the patient would be moving to the left with
respect to the beam) the y-shift in the coordinate axis is the opposite sign. The same method can
then be applied to the ±y-direction shifts with respect to the beam.

±𝑥 = ±𝑑cos(ϴ)
±𝑦 = ±𝑑𝑠𝑖𝑛(ϴ)
Equation 4- y-Direction shift with respect to the electron beam.
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In Equation 4, like before, x and y-direction shifts are denoted in the coordinate system x y and yy
to show that they are for y-direction shifts with respect to the beam. Notice that for this case,
moving towards the beam means that both x and y are negative, and away from the beam results
in x and y being negative. It is important to note that for an x, y, z-direction shift cases, to adjust
the total x and y coordinate axis shift to match the direction of the beam, you would simply add
xx and xy together, following suite for y-directions.
𝑥

=𝑥 +𝑥

𝑦

=𝑦 +𝑦

Equation 5- Total shift with respect to the electron beam for x, y, and z-direction shifts.

Once the patients are shifted in all directions, the minimum and maximum shifts in each
case will be analyzed to determine if the patient is still sufficiently treated (if the PTV still is
getting the prescribed 60 Gy dose) and if the OAR are still safe (are any of the threshold values
passed for each OAR). The OAR threshold values for the organs listed above for each brain case
were obtained from Orlando Health and are listed below.
Table 3.1- Threshold values for Nose Brow case OAR

Organs at Risk
Eyes L/R
Lens L/R

Threshold
 Maximum dose < 60 Gy
 Mean dose < 35 Gy
 Maximum dose < 25 Gy
Table 3.2- Threshold values for Brain case OAR.

Organs at Risk
Parotid Gland

Temporal Lobe
Oral Cavity

Threshold
 Mean dose < 26 Gy
 50% volume < 30 Gy
 20 cc < 20 Gy
 Maximum dose < 60 Gy
 1% volume < 65 Gy
 Mean dose < 40 Gy

29

CHAPTER 4: RESULTS AND ANALYSIS
Original Cases Comparison
As previously discussed in the Methodology, the first step to fully answering the research
question and confirming or disproving the hypothesis is to compare the three original cases to
each other for each patient. These include the original, conventional electron therapy without
intensity modulation or bolus, the case with the bolus applied, and the case with intensity
modulation and the bolus applied. This comparison will determine if IMET is the superior
method of treating cancer as opposed to a plan with only a bolus.
First, let us compare the Nose Brow case without any bolus or intensity modulation to
with just a bolus. In the DVH below, the solid line will represent the traditional case, and the
dotted will be the plan with the additional of the bolus. As mentioned before, in order to be
considered a better treatment method, the trendline of the PTV must be closer to the case where
100 percent of the volume absorbs 100 percent of the dose (which in both cases is 60 Gy). The
closer the trendlines of the PTV are to this “square”, which will defined as the “perfect DVH”,
the better the patient is treated overall.
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Figure 4.1- DVH of conventional electron therapy vs with bolus case (Nose Brow).

In Figure 4.1 it is seen that the dotted line, which signifies the plan with a bolus applied,
is closer to the prescribed dose of 60 Gy than the solid line, which is the traditional electron
therapy case without any bolus or intensity modulation. With the bolus applied, the trendline is
closer to the perfect DVH, meaning the patient’s target volume is treated more efficiently. The
Nose Brow patient will be looked at again, but this time the intensity modulation (IM) will be
added to the graph to see how it compares to the only bolus and original case. Each figure will
have what each line stands for above the graph. For example, in Figure 4.2 below, the solid line
represents the case without any bolus or IM, the dotted represents the only bolus case, and the
dashed line represents the case with both a bolus and IM applied.
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Figure 4.2- DVH of conventional electron therapy vs only bolus case vs with IM (Nose Brow).

Here, the dashed line is added, representing the case with bolus and IM. It is seen that
this new method is closer to the perfect DVH. This means that when compared to the only bolus
case, the plan with IM lessens the intensity of the hotspots (the bottom right of the trendline
absorbs less maximum dose) and coldspots (the “shoulder” on the top right of the trendline is
closer to the prescribed dose of 60 Gy). This shows that for this patient, the target volume is
treated more efficiently with the application of IM. Now the same procedure will be applied
with the other patient; the Brain case.
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Figure 4.3- DVH of conventional electron therapy vs with bolus case (Brain).

In the above DVH shown in Figure 4.3, much like in Figure 4.1, the solid line represents
the traditional case, and the dotted line represents the case with the bolus added. Now the same
DVH will be compared to the case with the addition of IM in Figure 4.4.
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Figure 4.4- DVH of conventional electron therapy vs only bolus case vs with IM (Brain).

This case is peculiar, because in Figure 4.3 the original case is closer to the perfect DVH.
In Figure 4.4, the IM case (the dashed line) is performing better than the case with only the
bolus, but still not efficient enough to match the traditional case without any added features.
Why is that? Recall that when radiation therapy was first introduced, it was stated that it is easy
to destroy the cancer inside the body. The problem medical physicists are faced with is limiting
the damage to the surrounding healthy organs. So, in Figures 4.3 and 4.4, the traditional case is
the best option because it does not do anything to prevent damage to the OAR. Below in Figure
4.5, the same DVH will be analyzed as in Figure 4.4, but this time including the OAR dose
distribution as well. In Figure 4.5 below, the yellow-colored trendlines are the right temporal
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lobe, the purple trendlines are the parotid gland, and the brown trendlines are the oral cavity,
which will be the case for the rest of the study.

Figure 4.5- DVH of conventional electron therapy vs only bolus case vs with IM including OAR (Brain).

As expected, for each OAR the traditional case sees much more radiation absorbed. It
can now be concluded that overall, the IM case performs better than the case with only the bolus
and the traditional case at treating the target volume and limiting the radiation absorption of vital
organs at risk.
Patient Shifts to Verify OAR Safety
Shifts Perpendicular to Electron Beam
The focus will now be on shifting each patient treated with intensity modulation with
respect to the beam in different directions and comparing the data obtained for each OAR to the
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threshold values obtained from Orlando Health listed in Tables 3.1 and 3.2. This will determine
if shifting the patient will disrupt the IM plan to the point where OAR are in danger, determining
if intensity modulation can still be implemented in real world patient care.
As seen in the last section, the Nose Brow case will be analyzed first. This case will
demonstrate how shifting the patient will affect OAR. Shown below in Figure 4.6 is a visual of
the original IM case (left) compared to a positive 5 mm shift (middle) and a negative 5 mm shift
(right) in the x-direction.

Figure 4.6- Visual of x-direction shifts compared to original (Nose Brow). Left is with no shift, middle is with positive 5 mm xshift, and right is with negative 5 mm x-shift.

As discussed in the Methodology, the coordinates indicate that a positive x-direction shift
would be to the patient’s left, and a negative would be to the patient’s right. Both of these agree
with the images above, considering the positive z-direction is into the page. This means that the
positive x-direction will be to the right in Figure 4.6 (which is the patient’s left because of the
way they are oriented), and the positive y-direction will be towards the bottom of Figure 4.6
(which is toward the patient’s back).
An example of the comparison between the no shift IM case (left) to the other
perpendicular shift case in the positive (middle) and negative (right) z-direction is also shown
below in Figure 4.7.
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Figure 4.7- Visual of z-direction shifts compared to original (Nose Brow). Left is with no shift, middle is with positive 5 mm zshift, and right is with negative 5 mm z-shift.

The coordinates in this example indicate that a positive z-shift with respect to the beam would be
towards the top of the head, and a negative towards the feet, both shown in Figure 4.7.
Now, the effect of a positive x-direction shift will be evaluated with a focus on the left
eye of the IM case. Keeping in mind that positive x-direction is towards the left, it should be
seen that the left eye (green-colored lines) and left lens (pink-colored lines) should be absorbing
more radiation with each shift, considering that the beam is moving closer to the eye with each
shift. By focusing on the left eye, it is easier to demonstrate how shifting the patient in one
direction impacts a specific OAR. If there were to be a focus on the right eye, the same results
would be found but with shifts in opposite directions.
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Figure 4.8- Effect of positive x-direction shifts on Nose Brow patient with focus on left eye.

As expected, shifting the patient to the left proved to jeopardize the left eye. For each
shift, listed above the graph in Figure 4.8, both the left eye and lens absorbed more radiation. If
the patient were to shift to the right (negative x-direction), the opposite effect should be observed
because the beam would be moving farther away from the left eye. This effect is shown below
in Figure 4.9. As mentioned previously, if the focus was on the right eye a positive x-direction
shift would benefit the right eye, and a negative shift should harm this OAR.
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Figure 4.9- Effect of negative x-direction shifts on Nose Brow patient with focus on left eye.

Shifting the patient to the right proved to save the left eye from the incoming radiation.
Now, the comparison of the minimum and maximum shifts in the positive x-direction to the
threshold values from Table 3.1 will be evaluated to determine if shifting the patient will damage
any OAR beyond any threshold values.
Table 4.1- Mean Dose (Gy) absorbed of Nose Brow case OAR with positive x-direction shifts.

Name

Original Case

PTV
Left Eye
Right Eye
Left Lens
Right Lens

64.431
33.176
30.791
32.522
31.027

Positive 1 mm
Shift
64.375
34.469
29.340
34.500
29.021
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Positive 5 mm
Shift
65.478
41.492
24.052
44.223
22.302

Threshold
Value
N/A
< 35
< 35
N/A
N/A

Table 4.2- Maximum Dose (Gy) absorbed of Nose Brow case OAR with positive x-direction shifts

Name

Original Case

PTV
Left Eye
Right Eye
Left Lens
Right Lens

76.600
59.728
56.453
44.610
41.599

Positive 1 mm
Shift
74.210
60.443
55.762
46.762
39.439

Positive 5 mm
Shift
76.170
65.130
51.607
55.541
32.354

Threshold
Value
N/A
< 60
< 60
< 25
< 25

Treating this patient, even in the case without any shift, there are threshold values being
surpassed. In the maximum dose absorbed shown in Table 4.2, in the original case with no shift,
both lenses are well past the threshold value of max dose not exceeding 25 Gy. This case shows
what is not acceptable, highlighted above in Tables 4.1 and 4.2, in the project’s overall objective.
In reality, including the case without IM, this patient could still be treated because there are
special lenses placed over the patient’s eyes which block incoming radiation. So, the OAR could
be saved and not exceed the threshold values for this case in particular. In some extreme cases,
the clinic and medical physicists may decide to treat the patient if threshold values are passed
regardless, because either the cancer itself will damage the OAR if nothing is done, or to prevent
the cancer from spreading to other parts of the body that can result in further complications or
ultimately death. In some cases, it may be better to treat the cancer and affect the OAR and not
risk further severe consequences.
The Nose Brow case is special because even without any shift, it was found that the
threshold values are passed. This case demonstrated the effects of shifting the patient with
respect the beam on the OAR. The Brain case will now be studied. In this plan, the original IM
case with no shift does not surpass any threshold values. Unlike the Nose Brow case, there are
no special lenses that can be put on the patient to protect OAR for the Brain case, meaning that
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through these shifts we will be able to determine if shifting the patient up to 5 mm (2 mm over
hospital setting) will still sufficiently treat the patients. It will also be determined if the OAR are
at risk, and if intensity modulation can be implemented for this patient.
As mentioned in the Methodology, the minimum and maximum shifts with respect to the
beam in the x-direction, z-direction, x and z-direction, and finally the x, y, and z-direction will be
analyzed. Once this is observed, the y-direction case, or the case direction of the beam, will be
analyzed to determine how this special case compares to perpendicular shifts. At each shift,
there will be a comparison of data obtained to the threshold values of the OAR found in Table
3.2. Shown below in Figure 4.10 is a visual of the original IM case (left) compared to a positive
5 mm shift (middle) and a negative 5 mm shift (right) in the x-direction with respect to the
electron beam.

Figure 4.10- Visual of x-direction shifts compared to original (Nose Brow). Left is with no shift, middle is with positive 5 mm xshift, and right is with negative 5 mm x-shift.

Similar to Figure 4.6, the positive x-direction shifts show a shift to the patient’s left with
respect to the beam, and opposite for the negative shift. Now the DVH for the minimum and
maximum shifts will be examined and data collected will be compared to the OAR threshold
values. For the remainder of the DVH graphs studied, the magenta-colored lines represent the
PTV, the yellow lines represent the right temporal lobe, the purple lines represent the parotid
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gland, and the brown lines represent the oral cavity. The solid lines represent the IM case with
no shift, and the representation of the other lines are found above each graph in the figures
below.

Figure 4.11- Effect of positive x-direction shifts on Brain case patient.

In Figure 4.11 above, the target is still sufficiently treated. As for the OAR, the right
temporal lobe and the parotid are both absorbing less radiation as the patient shifts to the left of
the incoming electron beam. The oral cavity, on the other hand, is receiving more radiation
when moving in this direction.
Below in Figure 4.12, the same DVH is shown but with shifts in the negative x-direction.
Each OAR should see the opposite effect due to shifts when compared to the case above in
Figure 4.11.
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Figure 4.12- Effect of negative x-direction shifts on Brain case patient.

As expected, the opposite effects on the OAR are observed for a shift in the other
direction. Note that the PTV is still sufficiently treated when shifted in both directions. Utilizing
Table 3.2, it will be determined if any threshold values are exceeded for all OAR in the Brain
case. Mean dose, maximum dose, total percent volume, and volume in cc will all be analyzed to
verify that no threshold limit is passed.
Table 4.3- Mean Dose (Gy) absorbed of Brain case OAR with positive x-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Positive 1 mm
Shift
63.967
12.184
16.492
7.241
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Positive 5 mm
Shift
64.989
8.342
15.359
8.125

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.4- Mean Dose (Gy) absorbed of Brain case OAR with negative x-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Negative 1 mm
Shift
63.965
14.710
17.173
6.869

Negative 5 mm
Shift
65.416
21.117
18.941
6.303

Threshold
Value
N/A
< 26
N/A
< 40

From Tables 4.3 and 4.4, all mean dose thresholds are not surpassed when shifted in
positive and negative x-directions. It is important to note these tables show how intensity
modulation targets the PTV. The mean dose for the tumor is 63.930 without any shift, with the
next highest being 16.797 in the temporal lobe. When compared to the OAR, the PTV mean
dose absorbed is much higher, showcasing that the planned beam is hitting the target with
accuracy. Now the maximum dose thresholds will be evaluated.
Table 4.5- Maximum Dose (Gy) absorbed of Brain case OAR with positive x-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Positive 1 mm
Shift
71.500
53.122
55.573
47.410

Positive 5 mm
Shift
71.760
46.335
55.539
50.490

Threshold
Value
N/A
N/A
< 60
N/A

Table 4.6- Maximum Dose (Gy) absorbed of Brain case OAR with negative x-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Negative 1 mm
Shift
72.110
56.243
55.902
45.960

Negative 5 mm
Shift
75.420
62.275
58.320
44.159

Threshold
Value
N/A
N/A
< 60
N/A

From Tables 4.5 and 4.6, it is seen that all maximum dose thresholds are not surpassed
when shifted in both directions. The cumulative percent volume threshold will be evaluated
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next. The threshold states that if 50 percent of the total parotid gland volume absorbs more than
30 Gy of radiation, and if 1 percent of the total temporal lobe volume absorbs more than 65 Gy
of radiation, the patient cannot be treated with this plan.

Figure 4.13- DVH of % volume threshold verification for x-direction shifts.

The maximum absorption 50 percent of the parotid gland (purple lines) experience, with
a negative 5 mm shift, and is about 18 Gy, which is under the 30 Gy threshold. As for the
temporal lobe (yellow lines), 1 percent of the total volume absorbs 58 Gy, which is also
considered safe according to Table 3.2. Finally, the cc volume threshold will be verified, which
states 20 cc of the parotid gland cannot exceed 20 Gy.
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Figure 4.14- DVH of cc volume threshold verification for x-direction shifts.

At 20 cc of the parotid gland, the dose absorbed is around a maximum of 3 Gy, which is
not close to the 20 Gy limit. This means that in total for x-direction shifts, no threshold limit is
passed, meaning the OAR are safe. Still, the same process must be repeated for z, x and z, and x,
y, and z-direction shifts, evaluating each to verify that all the threshold values for each OAR are
not surpassed. This will confirm that the OAR are not in danger when shifting the patient with
respect to the beam in any direction.
In the following tables and figures, the same process above is repeated, analyzing the
positive and negative shifts in each direction listed above. The final analysis of all perpendicular
shifts with respect to the beam will then be concluded following the results obtained below.
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Figure 4.15- Effect of positive z-direction shifts on Brain case patient.
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Figure 4.16- Effect negative z-direction shifts on Brain case patient.
Table 4.7- Mean Dose (Gy) absorbed of Brain case OAR with positive z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Positive 1 mm
Shift
64.086
13.212
16.856
6.883

Positive 5 mm
Shift
64.895
8.342
17.979
6.043

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.8- Mean Dose (Gy) absorbed of Brain case OAR with negative z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Negative 1 mm
Shift
64.178
13.937
16.371
7.325
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Negative 5 mm
Shift
65.217
15.933
15.536
8.395

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.9- Maximum Dose (Gy) absorbed of Brain case OAR with positive z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Positive 1 mm
Shift
71.260
54.059
55.822
46.040

Positive 5 mm
Shift
74.760
53.756
58.688
42.539

Threshold
Value
N/A
N/A
< 60
N/A

Table 4.10- Maximum Dose (Gy) absorbed of Brain case OAR with negative z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Negative 1 mm
Shift
70.820
54.688
55.580
48.304

Negative 5 mm
Shift
72.820
56.804
56.193
53.388

Figure 4.17- DVH of % volume threshold verification for z-direction shifts.
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Threshold
Value
N/A
N/A
< 60
N/A

Figure 4.18- DVH of cc volume threshold verification for z-direction shifts.
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Figure 4.19- Effect of positive x and z-direction shifts on Brain case patient.
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Figure 4.20- Effect of negative x and z-direction shifts on Brain case patient.

Table 4.11- Mean Dose (Gy) absorbed of Brain case OAR with positive x and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Positive 1 mm
Shift
64.129
12.016
16.533
7.069

Positive 5 mm
Shift
66.197
7.455
16.477
7.016

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.12- Mean Dose (Gy) absorbed of Brain case OAR with negative x and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Negative 1 mm
Shift
64.170
15.279
16.709
7.136
52

Negative 5 mm
Shift
66.230
23.990
17.351
7.504

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.13- Maximum Dose (Gy) absorbed of Brain case OAR with positive x and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Positive 1 mm
Shift
72.370
52.386
55.650
46.692

Positive 5 mm
Shift
76.120
44.698
57.473
46.148

Threshold
Value
N/A
N/A
< 60
N/A

Table 4.14- Maximum Dose (Gy) absorbed of Brain case OAR with negative x and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Negative 1 mm
Shift
72.420
56.029
55.836
47.490

Negative 5 mm
Shift
77.980
63.680
58.100
51.102

Threshold
Value
N/A
N/A
< 60
N/A

Figure 4.21- DVH of % volume threshold verification for x and z-direction shifts.
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Figure 4.22- DVH of cc volume threshold verification for x and z-direction shifts.
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Figure 4.23- Effect of positive x, y, and z-direction shifts on Brain case patient.
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Figure 4.24- Effect of negative x, y, and z-direction shifts on Brain case patient.
Table 4.15- Mean Dose (Gy) absorbed of Brain case OAR with positive x, y, and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Positive 1 mm
Shift
64.801
9.303
16.398
6.991

Positive 5 mm
Shift
66.342
7.314
16.412
6.953

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.16- Mean Dose (Gy) absorbed of Brain case OAR with negative x, y, and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

63.930
13.403
16.797
7.048

Negative 1 mm
Shift
64.906
19.577
17.164
7.373
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Negative 5 mm
Shift
66.049
24.234
17.460
7.555

Threshold
Value
N/A
< 26
N/A
< 40

Table 4.17- Maximum Dose (Gy) absorbed of Brain case OAR with positive x, y, and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Positive 1 mm
Shift
73.450
49.025
55.548
46.655

Positive 5 mm
Shift
77.070
44.552
57.410
45.990

Threshold
Value
N/A
N/A
< 60
N/A

Table 4.18- Maximum Dose (Gy) absorbed of Brain case OAR with negative x, y, and z-direction shifts.

Name

Original Case

PTV
Parotid Gland
Temporal Lobe
Oral Cavity

70.480
54.545
55.760
46.721

Negative 1 mm
Shift
72.960
59.761
56.990
49.784

Negative 5 mm
Shift
77.850
63.434
57.935
50.886

Threshold
Value
N/A
N/A
< 60
N/A

Figure 4.25- DVH of % volume threshold verification for x, y, and z-direction shifts.
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Figure 4.26- DVH of cc volume threshold verification for x, y, and z-direction shifts.

The data found shows that even with maximum shifts of 5 mm in all directions, all of the
OAR mean and maximum dose values, total percent volumes, and total cc volumes do not pass
any thresholds. This means that in total, the homogeneity of the intensity modulated dose
prevents the patient plans from being disrupted to the point where it is unsafe to treat patients
with IMET. The patient in each case is still sufficiently treated, and the vital organs are not in
danger. This confirms the hypothesis and answers the research question. Now the special case
must be studied; the y-direction patient shifts, which are in the direction of the beam.
Shifts in Direction of Electron Beam
Here the special case of shifting the patient in the same direction as the incoming
electrons will be analyzed. As explained in the Methodology, there should not be as drastic of a
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difference in shifting the patient as when compared to the perpendicular cases investigated above
due to the overall cone-like shape of the electron beam deliverance. Below in Figure 4.27 are
visuals of shifting the Brain case patient with respect to the beam.

Figure 4.27- Visual of y-direction shifts compared to original (Nose Brow). Left is with no shift, middle is with positive 5 mm yshift (away from beam), and right is with negative 5 mm y-shift (towards beam).

Unlike in Figure 4.10, it is more difficult to distinguish the shifts in the patient in both
directions from the original case, as expected. The DVH comparing positive y-direction shifts
compared to the IM case with no shifts will now be evaluated, followed by the negative ydirection shifts. This should show a much closer looking dose distribution as compared to a
perpendicular shift case, like in Figures 4.11 and 4.15 previously studied. These shifts are shown
in Figures 4.28, the positive y-shift, and 4.29, the negative y-shift below.
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Figure 4.28- Effect of positive y-direction shifts on Brain case patient.
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Figure 4.29- Effect negative y-direction shifts on Brain case patient.

It is clearly shown in both DVH’s that the PTV and OAR do not undergo any dramatic
changes in dose distribution when compared to the original case. Consequently, the shifts in the
patient with respect to the electron beam has negligible effect on dose distribution, confirming
proposition discussed in the methodology.
Same Shift Comparison Between IMET and Only Bolus Case
Next, the same shift of the IMET plan will be compared to the plan with only the
application of the bolus. This comparison has already been seen earlier in the results, and saw
the IM case’s PTV trendline lie closer to the perfect DVH trendline, making it the more effective
and efficient plan. Now, the IMET plan will be compared to only bolus plan, focusing on the
OAR dose distribution when shifting both cases 3 mm, which is the typical clinical setting limit.
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IMET delivers a more homogeneous dose, so the OAR should absorb slightly more radiation
than the only bolus case. This is due to the fact that hotspots receive less radiation, likewise the
coldspots receive more. However, it was already determined in the last section that no OAR are
in danger of being damaged because no threshold values were surpassed when shifted 5 mm in
any direction.

Figure 4.30- DVH of comparison between only bolus case (solid line) and IM case (dotted line) with 3 mm x-shift. (Brain case).

When comparing the two cases with the same 3 mm shift, the IM case treats the PTV
more efficiently, and the OAR are slightly in the same range for dose distribution. This is also
shown with the other 3 mm shifts in z, x and z, and x, y, and z-directions, which all produce
similar DVH’s. Each case showed the exact same result of IM having lesser hotspots and
coldspots and slightly more dose absorbed by the OAR but not to the point where the patient
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cannot be treated. In the table below, the mean dose (Gy) of the IM case shift and only bolus
case shift will be analyzed and compared, to determine how much more radiation each OAR
absorbs.
Table 4.19- Mean dose (Gy) of each OAR in IM case vs only bolus case (both with 3 mm x-shift).

Name
Parotid Gland
Temporal Lobe
Oral Cavity

Mean Dose of IM (Gy)
10.050
15.881
7.659

Mean Dose of Only Bolus (Gy)
9.823
15.780
7.539

The mean dose of each OAR with IM was larger by approximately 0.1 Gy for each organ,
as shown in Table 4.19. In conclusion, due to the more homogeneous dose produced through
intensity modulation, the OAR absorb approximately 0.1 Gy more dose than when compared to
the electron treatment plan with only a bolus applied, as expected. This slightly higher dose
distribution does not surpass the threshold limits listed in Table 3.2 as displayed in the last
section.
Comparison of Shift Spread
Lastly, the comparison of the shift spreads of the intensity modulated plan and the plan
including only the bolus will be analyzed to determine if clinics that will administer IMET need
to change their practices to accommodate for the addition of intensity modulation. The spread of
radiation absorbed at a given volume of an OAR between ±3 mm x-shifts will be examined. For
this project, 50 percent volume of the parotid gland was evaluated, though any OAR and percent
volume would meet the requirements of the objective. If the spread of the radiation absorbed by
the OAR is not drastically different in the IM case compared to the only bolus case, then the
clinics will not need to change their approach to deliver IMET to the patient, which is important
to hospitals applying this plan to patients.
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In the DVH’s shown below in Figures 4.31 and 4.32, which showcase the dose
distribution spread for the IM plan and the only bolus plan, a red line is included at the 50
percent cumulative volume of the parotid gland to help visualize and mark the total spread.

Figure 4.31- ±3 mm x-shift dose distribution spread for 50 % total volume of parotid gland (IM plan).

It is shown that 50 percent of the total volume of the parotid gland with a 3 mm shift to
the left (positive x-direction) with respect to the beam absorbs approximately 7 Gy. When
shifted to the right (negative x-direction), it absorbs approximately 15 Gy. Therefore, for the IM
plan, there is a dose distribution spread of about 8 Gy. Now the same process for the only bolus
plan will be evaluated. Again, the shift spread for 50 percent of the total volume of the parotid
gland will be studied.
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Figure 4.32- ±3 mm x-shift dose distribution spread for 50 % total volume of parotid gland (only bolus plan).

In Figure 4.32 above it is shown that 50 percent total volume of the parotid gland at a 3
mm shift to the left corresponds to about a 7 Gy electron absorption, similar to the IM plan. For
a 3 mm shift to the right, again both are close to 15 Gy. Therefore, both cases showed similar
dose distribution spread of 8 Gy, meaning the uncertainties were not increased with intensity
modulation. Clinics will not need to change practices to treat patients with intensity modulation.
It is also important to notice the differences in the drop offs for each PTV trendline above. Seen
again, in the IM plan the PTV trendline had a steeper drop off when compared to the only bolus
plan, making it closer to the perfect DVH and the overall better method.
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CHAPTER 5: CONCLUSION
Answering the Research Question
The goal for this project was to determine if IMET provided a better alternative to
conventional electron therapy and treatment with the addition of a bolus. IMET is formulated on
a patient’s original orientation, so this project also focused on finding out if shifting the patient
would disrupt the formulated plan and harm any OAR in the patient, and if the PTV would still
be sufficiently treated. This project also evaluated if clinics would need to change their practices
to treat patients with IMET.
It was determined that IMET produces both a conformal and uniform dose distribution,
making it the overall better treatment plan than conventional electron therapy with the addition
of only a bolus. The PTV was still sufficiently treated with less intense hotspots and coldspots
than the treatment plan without any intensity modulation. With the homogeneous dose
produced, it was determined that with maximum shifts of 5 mm (2 mm over the hospital limit) in
all directions, no OAR threshold limits were passed. This means that even if the patient were to
move, the IMET plan would still provide a safe, superior method of treating cancer. Finally, it
was also found that the dose distribution spread of IMET and the case with only a bolus were
approximately the same, but with IMET delivering a more efficient treatment of the PTV. So,
clinics would not need to change practices to deliver IMET to patients.
Next Steps in Research
Overall, the project was successful, but further work is still needed before IMET can be
implemented in the real world. This experiment showed that even though the patient is moving,
which skews the IM plan formulated to the patient’s original position, the homogenous, uniform
dose still treats the patient adequately. Still, further testing must be done on more cases of
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electron therapy in order to move the project to the next step. With more patients providing the
same results found, this project will be able to reach the point of finally being utilized to help
treat patients with cancer and other illnesses in the future.
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